Zolpidem

Insomnia

Brasilia University HospitalSmall moleculePhase 4 / ApprovedDormant

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 89/ 100

Competitive context

10 Active assets in the Insomnia cohort.

Asset / Sponsor	Phase	Rating
Eszopiclone University of California, Los Angeles	Phase 4	A
Escitalopram University of California, Los Angeles	Phase 4	BBB
Suvorexant Mayo Clinic	Phase 4	BBB
Lemborexant YangPan	Phase 4	BBB
Gabapentin University of California, San Diego	Phase 3	BB

View all 40 →

Same molecule, other indications

Zolpidem is also rated in:

sleep disorder, initiating and maintaining sleepDormant

BB

Indicative · Phase 3

65 / 100

sleep disorderDormant

B

Indicative · Phase 3

62 / 100

major depressive disorderActive

B

Indicative · Phase 4

61 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.